BioCardia (NASDAQ:BCDA) Stock Price Up 12.1% – Time to Buy?

Posted by Stanley Muller on Jun 6th, 2026

BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) shares were up 12.1% on Friday . The stock traded as high as $1.80 and last traded at $1.03. Approximately 150,596,959 shares changed hands during mid-day trading, an increase of 39,885% from the average daily volume of 376,629 shares. The stock had previously closed at $0.9190.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioCardia has an average rating of “Hold” and an average price target of $25.00.

Check Out Our Latest Stock Report on BCDA

BioCardia Stock Performance

The company has a market cap of $11.72 million, a price-to-earnings ratio of -1.13 and a beta of 0.51. The business has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.22.

BioCardia (NASDAQ:BCDA – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). As a group, equities analysts anticipate that BioCardia, Inc. will post -0.71 EPS for the current year.

Institutional Investors Weigh In On BioCardia

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers bought a new position in shares of BioCardia during the second quarter worth about $40,000. DRW Securities LLC bought a new stake in BioCardia in the fourth quarter valued at approximately $72,000. Finally, Geode Capital Management LLC increased its position in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the period. Institutional investors and hedge funds own 20.57% of the company’s stock.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.